Workshop on biosimilars

EventCorporateBiosimilars

Norwegian is available via eTranslation, the European Commission's machine translation service.

Translate to Norwegian | Important information about machine translation

Date

Thursday, 31 October 2013, All day

Location

European Medicines Agency, Amsterdam, the Netherlands

The workshop is intended to discuss the draft guideline on similar biological medical products, the draft guideline on similar biological medical products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, and the draft guideline on similar biological medical products containing biotechnology-derived proteins as active substance: quality issues. Registration closed.

Documents

Agenda - Workshop on biosimilars

Reference Number: EMA/473908/2013

English (EN) (74.69 KB - PDF)

Først publisert: Sist oppdatert:
Vis

List of participants - Workshop on biosimilars

Reference Number: EMA/681299/2013

English (EN) (143.9 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - Draft revised guideline on similar biological medicinal products: Relevant changes (Martina Weise)

English (EN) (234.06 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - EBG’s comments on the draft revised guideline on similar biological medicinal products (Karl Heinz Emmert)

English (EN) (1.09 MB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - Guideline on similar biological medicinal products: Overarching guideline

English (EN) (734.59 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - Guideline on similar biological medicinal products containing biotechnologically-derived proteins as active substances: quality issues (Niklas Ekman)

English (EN) (159.22 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - EGA’s perspective on the draft quality guideline (Joerg Windisch)

English (EN) (922.36 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Quality issues

English (EN) (656.89 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (Niklas Ekman)

English (EN) (309.73 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (Hans-Karl Heim)

English (EN) (117.28 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - Guideline on Similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues (Pekka Kurki)

English (EN) (360.9 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - EBG’s perspective on the draft guideline on the non-clinical/clinical issues (Mark McCamish)

English (EN) (1.18 MB - PDF)

Først publisert: Sist oppdatert:
Vis

Presentation - Nonclinical and clinical considerations

English (EN) (571.74 KB - PDF)

Først publisert: Sist oppdatert:
Vis

Multimedia

Share this page